Skip to main content
Federal Lobbying Data · Senate LDA Filings · Updated Quarterly
LobbySpend

Bristol-Myers Squibb

Pharmaceutical & Health Products · Lobbying Client

Reviewed by LobbySpend Editorial Team · Updated
C
Influence Score
58/100
Moderate Influence
$24.8M
Total Lobby Spend
6
Policy Issues
17
Lobbyists
4
Revolving Door

Bristol-Myers Squibb's Federal Lobbying Record

At $24.8M in disclosed federal lobbying, Bristol-Myers Squibb ranks as a major spender — well above the typical filer. Outlays in this range generally reflect a sustained presence in Washington, with at least one full-time government affairs lead and a stable of outside lobbyists engaged on the organization's priority issues.

Across the 5-year window from 2020 to 2024, Bristol-Myers Squibb's annual disclosed lobbying spend has declined modestly — from $5.2M in 2020 to $4.9M in 2024, a change of -5%. Step-changes of this size often coincide with major bills moving through Congress, regulatory rulemakings affecting the organization's industry, or a leadership change in the relevant committee.

Bristol-Myers Squibb's disclosed lobbying covers 6 general issue areas — a moderate footprint. Filers in this range tend to engage on a coherent cluster of related topics rather than spreading effort across the federal agenda.

4 of 17 lobbyists reported by Bristol-Myers Squibb (24%) disclose prior federal government service — a small minority of the named bench.

Among the named bench, lobbyists with disclosed prior federal service include Barbara J. Wilson (Former Commissioner, FCC); Carol L. Stewart (Former Deputy U.S. Trade Representative); Robert J. McNamara (Former Counsel, Senate Commerce Committee). The covered-position field on LDA cover sheets captures executive-branch and senior congressional roles held within the prior two years.

Within the Pharmaceutical & Health Products sector, Bristol-Myers Squibb ranks #5 of 34 tracked organizations by disclosed lobbying spend. The sector leader is Pharmaceutical Research & Manufacturers of America at $135.8M; the sector average is $16.7M. Bristol-Myers Squibb's $24.8M sits 48% above the sector average.

Bristol-Myers Squibb's LobbySpend Influence Score of 58/100 (grade C) is the most common grade in the index — it covers organizations with established but moderate federal advocacy programs. The score combines disclosed total spend (40%), issue breadth (30%), and revolving-door connections (30%). A C-grade is typical of mid-size corporations and trade associations with steady quarterly filings on a focused issue set.

Every figure above is sourced from Senate lobbying disclosure filings submitted under the Lobbying Disclosure Act of 1995. Per-issue dollar splits and covered-position flags are filer-reported and may be amended after initial submission.

Track Bristol-Myers Squibb's lobbying filings

Subscribe for LobbySpend updates by email. No spam, unsubscribe anytime.

Annual Lobbying Spend

Policy Issues

Government Entities Contacted

Dept of Energy
U.S. Senate
Securities & Exchange Commission
Environmental Protection Agency
Dept of Defense
Dept of Homeland Security
Dept of Health & Human Services

Recent Filings

PeriodRegistrantIssuesLobbyistsAmount
2024 Oct-DecCornerstone Government Affairs
CPTHCRPHA+1
1$1.2M
2024 Jul-SepWilliams & Jensen
HCRTAXGOV
2$1.2M
2024 Apr-JunSummit Strategies Government Affairs
GOVHCRPHA+2
4$1.1M
2024 Jan-MarBrownstein Hyatt Farber Schreck
MEDPHAGOV+1
4$1.1M
2023 Oct-DecWilliams & Jensen
HCRPHACPT+2
2$1.1M
2023 Jul-SepPodesta Group
GOVPHAMED
3$1.1M
2023 Apr-JunSquire Patton Boggs
MEDGOVPHA+2
3$1.1M
2023 Jan-MarTarplin, Downs & Young
MEDTAXGOV
1$1.2M

Bristol-Myers Squibb Lobbying FAQ

Bristol-Myers Squibb has spent $24.8M on federal lobbying across 6 policy areas. This includes spending on registered lobbyists and direct government contacts.

Bristol-Myers Squibb lobbies on 6 policy issues, including Health Issues, Pharmacy, Medical/Disease Research, Copyright/Patent/Trademark. These disclosures are filed quarterly with the Senate Office of Public Records.

Bristol-Myers Squibb has an Influence Score of 58/100 (Grade C). This proprietary score is based on total lobby spend (40%), policy issue breadth (30%), and revolving door connections (30%).

Bristol-Myers Squibb employs 17 registered lobbyists, of whom 4 have revolving door connections, meaning they previously held government positions before becoming lobbyists.

Bristol-Myers Squibb has contacted 7 government entities as part of their lobbying activities, including Dept of Energy, U.S. Senate, Securities & Exchange Commission.

Sources: Senate Office of Public Records (LDA), OpenSecrets.org
Last updated:

Lobbying data is sourced from quarterly Lobbying Disclosure Act (LDA) filings with the Senate Office of Public Records. Influence Scores combine total spend (40%), issue breadth (30%), and revolving door connections (30%). Filings may be amended after initial submission.